YNH-1Homo sapiens (Human)Cancer cell line
🤖 AI SummaryBased on 5 publications
Quick Overview
Human acute myeloid leukemia cell line with t(16;21) translocation
Detailed Summary
The YNH-1 cell line is a human acute myeloid leukemia (AML) cell line established from a patient with t(16;21) chromosomal translocation. This cell line exhibits characteristics of myeloid differentiation antigens and cytokine receptor expression, including high expression of CD34, CD11b, CD11c, CD13, CD14, CD33, and CD56. YNH-1 cells are dependent on granulocyte colony-stimulating factor (G-CSF) for proliferation and show resistance to differentiation. The cell line has been used in studies investigating the role of the FUS/ERG fusion gene and its implications in leukemogenesis. Additionally, YNH-1 has been utilized in research on cohesin mutations and their impact on myeloid neoplasms.
Research Applications
Study of t(16;21) chromosomal translocationInvestigation of FUS/ERG fusion geneAnalysis of cytokine receptor expressionResearch on cohesin mutations in myeloid neoplasms
Key Characteristics
Expresses CD34, CD11b, CD11c, CD13, CD14, CD33, and CD56Dependent on G-CSF for proliferationResistant to differentiationCarries t(16;21), t(16;1), and 12q13 translocations
Generated on 6/17/2025
Basic Information
| Database ID | CVCL_1927 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Disease Information
| Disease | Acute myeloid leukemia |
|---|
DepMap Information
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | PTPN11 | p.Glu76Gly (c.227A>G) | Unspecified | - | PubMed=16518851 |
| Gene fusion | ERG | FUS-ERG, TLS-ERG | - | In frame | PubMed=10354136, PubMed=9096702 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X,Y
CSF1PO
11,12
D10S1248
12,13
D12S391
17,20
D13S317
8,13
D16S539
9
D18S51
14,15
D19S433
14
D1S1656
17
D21S11
29,30
D22S1045
15,16
D2S1338
20,25
D2S441
9.1,11
D3S1358
15,16
D5S818
11,12
D7S820
11,13
D8S1179
12,13
DYS391
11
FGA
19,20
Penta D
11,12
Penta E
5,11
TH01
6,9
TPOX
11,12
vWA
14,16
Publications
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Haferlach T., Shirahige K., Miyano S., Ogawa S.
Nat. Genet. 45:1232-1237(2013).
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Hongo T., Taki T., Ogasawara M., Shimada A., Hayashi Y.
Genes Chromosomes Cancer 45:583-591(2006).
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Tsuchida M., Sugita K., Ida K., Hayashi Y.
Blood 103:1085-1088(2004).
p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization?
Uphoff C.C.
Leukemia 14:198-206(2000).
Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells with t(16;21)(p11;q22): frequent expression of CD56 and interleukin-2 receptor alpha chain.
Oka K., Hamaguchi H., Kyo T., Tanaka K., Kamada N., Kita K.
Br. J. Haematol. 105:711-719(1999).
Establishment of a novel human acute myeloblastic leukemia cell line (YNH-1) with t(16;21), t(1;16) and 12q13 translocations.
Taniwaki M.
Leukemia 11:599-608(1997).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).